14 research outputs found
KoÅ”tana pregradnja pomoÄu osteoklasta: Å”to smo nauÄili iz ispitivanja knockout gena?
Osteopetroses are disorders of bone remodeling resulting in increased bone mass. Osteopetrosis abnormalities can include changes in osteoclast lineage, bone marrow microenvironment, or both. Little is known about the mechanisms that regulate the activity of different bone cell types. Various agents act on bone in a complicated web of interactions, with either synergistic or diverse effects. Advances in molecular biology have enabled studies in knockout or transgenic animals, providing an insight into the mechanism of bone remodeling.Osteopetroze su poremeÄaji pregradnje kostiju koji dovode do poveÄanja koÅ”tane mase. OsteopetrotiÄne abnormalnosti mogu obuhvaÄati promjene u staniÄnoj liniji osteoklasta, u mikrookoliÅ”u koÅ”tane srži ili oboje. Malo se zna o mehanizmima koji reguliraju aktivnost razliÄitih vrsta koÅ”tanih stanica. RazliÄiti Äimbenici utjeÄu na kost kroz Äitav splet meÄusobnih aktivnosti sa sinergistiÄnim ili raznovrsnim uÄincima. Napredak u molekularnoj biologiji omoguÄio je ispitivanja na knockout ili transgenskim životinjama, pružajuÄi uvid u mehanizme koÅ”tane pregradnje
KliniÄka imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege [Tumor immunotherapy in clinical setting based on the blockade of molecular interactions of the negative feedback mechanism]
The recent successful results of several relatively new immunotherapeutic anti-cancer strategies such as the blockade of immune inhibitory pathways by monoclonal antibodies against checkpoint molecules can be considered as a medical breakthrough in clinical cancer immunotherapy. This paper presents a basic overview of cancer immunoediting and the clinical application of monoclonal antibodies against checkpoint molecules in cancer patients. Interactions between the immune system and the malignancy are complex, but the results obtained by using the above mentioned therapeutic approaches indicate acceptable clinical utility, efficacy and safety against several types of cancer. Clinical application of monoclonal antibodies against checkpoint molecules CTLA-4, PD-1, and PD-L1, depending on which tumors these antibodies are tested and applied against, ranges from their already usage having been approved by regulatory agencies for patients with particular metastatic tumors to their testing in clinical studies with the aim of demonstrating their efficiency and consequently obtaining approval
TUMOR IMMUNOTHERAPY IN CLINICAL SETTING BASED ON THE BLOCKADE OF MOLECULAR INTERACTIONS OF THE NEGATIVE FEEDBACK MECHANISM
Nedavni uspjeÅ”ni rezultati viÅ”e raznih novih imunoterapijskih pristupa u onkoloÅ”kih bolesnika, kao, primjerice, blokada imunosnih inhibitornih molekularnih interakcija s monoklonskim protutijelima protiv molekula kontrolnih toÄaka, mogu se smatrati medicinskim iskorakom u kliniÄkoj onkologiji. Cilj je ovoga rada dati pojednostavnjeni prikaz imunosnog ureÄivanja raka i kliniÄke primjene monoklonskih protutijela protiv molekula kontrolnih toÄaka u onkoloÅ”kih bolesnika. Interakcije izmeÄu imunosnog sustava i autolognih tumora složene su, ali rezultati dobiveni primjenom monoklonskih protutijela protiv molekula kontrolnih toÄaka upuÄuju na prihvatljivu kliniÄku primjenjivost, uÄinkovitost i sigurnost u lijeÄenju bolesnika s odreÄenim tipovima raka. KliniÄka primjena monoklonskih protutijela protiv molekula kontrolnih toÄaka CTLA-4, PD-1 i PD-L1, ovisno o tome protiv kojih se tumora ta protutijela testiraju i primjenjuju, jest u rasponu od odobrenja regulatornih agencija i primjene u metastatskoj bolesti u bolesnika s odreÄenim vrstama tumora pa do faza testiranja u kliniÄkim studijama, a radi istraživanja kliniÄke uÄinkovitosti i dobivanja odobrenja.The recent successful results of several relatively new immunotherapeutic anti-cancer strategies such as the blockade of immune inhibitory pathways by monoclonal antibodies against checkpoint molecules can be considered as a medical breakthrough in clinical cancer immunotherapy. This paper presents a basic overview of cancer immunoediting and the clinical application of monoclonal antibodies against checkpoint molecules in cancer patients. Interactions between the immune system and the malignancy are complex, but the results obtained by using the above mentioned therapeutic approaches indicate acceptable clinical utility, efficacy and safety against several types of cancer. Clinical application of monoclonal antibodies against checkpoint molecules CTLA-4, PD-1, and PD-L1, depending on which tumors these antibodies are tested and applied against, ranges from their already usage having been approved by regulatory agencies for patients with particular metastatic tumors to their testing in clinical studies with the aim of demonstrating their efficiency and consequently obtaining approval
TUMOR IMMUNOTHERAPY IN CLINICAL SETTING BASED ON THE BLOCKADE OF MOLECULAR INTERACTIONS OF THE NEGATIVE FEEDBACK MECHANISM
Nedavni uspjeÅ”ni rezultati viÅ”e raznih novih imunoterapijskih pristupa u onkoloÅ”kih bolesnika, kao, primjerice, blokada imunosnih inhibitornih molekularnih interakcija s monoklonskim protutijelima protiv molekula kontrolnih toÄaka, mogu se smatrati medicinskim iskorakom u kliniÄkoj onkologiji. Cilj je ovoga rada dati pojednostavnjeni prikaz imunosnog ureÄivanja raka i kliniÄke primjene monoklonskih protutijela protiv molekula kontrolnih toÄaka u onkoloÅ”kih bolesnika. Interakcije izmeÄu imunosnog sustava i autolognih tumora složene su, ali rezultati dobiveni primjenom monoklonskih protutijela protiv molekula kontrolnih toÄaka upuÄuju na prihvatljivu kliniÄku primjenjivost, uÄinkovitost i sigurnost u lijeÄenju bolesnika s odreÄenim tipovima raka. KliniÄka primjena monoklonskih protutijela protiv molekula kontrolnih toÄaka CTLA-4, PD-1 i PD-L1, ovisno o tome protiv kojih se tumora ta protutijela testiraju i primjenjuju, jest u rasponu od odobrenja regulatornih agencija i primjene u metastatskoj bolesti u bolesnika s odreÄenim vrstama tumora pa do faza testiranja u kliniÄkim studijama, a radi istraživanja kliniÄke uÄinkovitosti i dobivanja odobrenja.The recent successful results of several relatively new immunotherapeutic anti-cancer strategies such as the blockade of immune inhibitory pathways by monoclonal antibodies against checkpoint molecules can be considered as a medical breakthrough in clinical cancer immunotherapy. This paper presents a basic overview of cancer immunoediting and the clinical application of monoclonal antibodies against checkpoint molecules in cancer patients. Interactions between the immune system and the malignancy are complex, but the results obtained by using the above mentioned therapeutic approaches indicate acceptable clinical utility, efficacy and safety against several types of cancer. Clinical application of monoclonal antibodies against checkpoint molecules CTLA-4, PD-1, and PD-L1, depending on which tumors these antibodies are tested and applied against, ranges from their already usage having been approved by regulatory agencies for patients with particular metastatic tumors to their testing in clinical studies with the aim of demonstrating their efficiency and consequently obtaining approval
Immunotherapy of kidney cancer
Rak je bubrega neoplazma koja je razmjerno otporna na postojeÄu kemoterapiju, hormonsko i iradijacijsko lijeÄenje, stoga se u lijeÄenju bolesnika s rakom bubrega primjenjuju i testiraju lijekovi ili terapije s imunomodulatornim djelovanjem. U kliniÄkoj praksi, a sa svrhom imunoterapije, najÄeÅ”Äe se primjenjuju rekombinantni citokini interferon-alfa (INF-a) i interleukin-2 (IL-2). Ta dva citokina mogu izazvati terapijski odgovor u 10% do 30% bolesnika s metastatskim rakom bubrega. DugoroÄno preživljenje ipak je rijetko, neÅ”to ÄeÅ”Äe u bolesnika koji su primali visokodozni IL-2. Kako lijeÄenje raka bubrega usprkos brojnim studijama s razliÄitim terapijama nije zadovoljavajuÄe, u tijeku su i kliniÄke studije s drugim imunoterapijskim postupcima.Renal cell carcinoma (RCC) is generally resistant to standard chemotherapy, hormonal or irradiation treatments. Therefore, various drugs or therapies with immunomodulatory action were or are tested in kidney cancer patients. In clinical praxis many approaches have been investigated of which interferon-alpha (INF-") and interleukin-2 (IL-2) are the most extensively studied ones. These two cytokines can achieve response rates in 10% to 30% of patients with metastatic RCC. Long-term survival, however, is achieved only in few patients. More frequently in the ones who have been receiving high-dose IL-2. Consequently, the treatment of RCC is far from being optimal. Therefore, other and novel immunotherapeutic strategies are ongoing or planned to be tested in clinical trials
HORMONAL THERAPY OF PROSTATE CANCER: ARE THERE ANY DILEMMAS LEFT?
Strategija lijeÄenja bolesnika s adenokarcinomom prostate ovisi o procjeni proÅ”irenosti bolesti, procjeni rizika od povratka bolesti, dobi, oÄekivanom trajanju života, komorbiditetima, afinitetima i naÄinu života. Jedan od standardnih terapijskih modaliteta jest i hormonska terapija. Hormonska terapija raka prostate zapravo je terapija koja suprimira androgen (AST) ili koja terapija deprivira androgen (ADT). Njezinom primjenom dolazi do sniženja razine androgena u krvi, a kako su stanice adenokarcinoma najveÄim dijelom (Ā³80%) hormonski ovisne o androgenima, prestanak stimulacije stanica raka androgenima dovodi do njihove apoptoze, usporava se rast tumora i smanjuje se njegova veliÄina. Stoga se ta vrsta terapije rabi u lijeÄenju karcinoma prostate. Hormonska terapija indicirana je kao prvi terapijski modalitet kod nalaza metastatske bolesti. U sluÄaju primjene radioterapije na prostatu zahvaÄenu rakom s kurativnom namjerom (kod nemetastatske bolesti) preporuÄuje se primjena terapije koja deprivira androgen u bolesnika sa srednjim i visokim rizikom od povratka bolesti prije, za vrijeme i poslije radioterapije u trajanju od 6 mjeseci ili 2ā3 godine ovisno o procijenjenom riziku od povratka bolesti. U vezi s primjenom terapije koja deprivira androgen, a koja se može primijeniti na viÅ”e naÄina i u viÅ”e kombinacija, za odreÄene kliniÄke situacije ne postoje konaÄne preporuke. Razloga je viÅ”e: premalen broj odgovarajuÄih kliniÄkih studija, heterogenost bolesnika u studijama Å”to otežava interpretaciju podataka te nekonzistentni rezultati. TakoÄer, kako novije dijagnostiÄke metode i postupci omoguÄavaju ranije otkrivanje raka prostate, a ranije i sve uspjeÅ”nije lijeÄenje produžava život bolesnika s metastatskom boleÅ”Äu, rezultati Ā»ranijihĀ« kliniÄkih studija mogu gubiti na aktualnosti. Isto tako, sa sve dužim preživljenjem bolesnika sve važnija postaje kvaliteta života, odnosno nuspojave lijeÄenja, kao i procjena koristi u odnosu prema Å”tetnosti same terapije. Cilj je prikaza da upozori na novije spoznaje, kao i na moguÄe dileme o mjestu i primjeni terapije koja deprivira androgen.The strategy for treating prostate cancer patients depends on the assessment of disease extent, assessment of the risk of disease relapse, assessment of life expectancy, comorbidities, affinities and life-style. Since the activity and survival of prostate cancer cells is at least initially dependent on androgen stimulation, hormonal therapy is one of the several standard treatment modalities. Hormonal therapy is aimed at decreasing this androgen stimulation either by lowering androgen production or by blocking receptor binding. Hormonal therapy is in fact androgen-suppressive therapy (AST) or androgen-deprivation therapy (ADT). If effective, it results in the lack of cancer cell stimulation, thus causing their apoptosis and consequently decline in tumor growth and size. Hormonal therapy is used as a first-line treatment modality for metastatic disease. In addition to this indication, hormonal therapy is also used as an adjunct to radiotherapy with curative intent for patients with non-metastic disease but having an intermediate and high risk of disease relapse. In combination with radiotherapy, hormonal therapy can be applied before, concomitantly and after radiotherapy for the duration of 6 months or 2 to 3 years depending on the risk estimation. Regarding hormonal therapy, it can be applied in combination with other treatments, in several ways, and sometimes there might be several options available. This possible lack of a specific recommendation is a consequence of the fact that there is a limited number of adequate clinical studies which, moreover, may have yielded inconsistent results sometimes simply due to the patientsā heterogeneity. Moreover, thanks to the newer and better diagnostic methods enabling the discovery of prostate cancer in earlier disease stages, as well as to the more effective treatments, there is also a prolongation of relapse-free survival and possibly of overall survival in patients having metastic disease. Consequently, the results of earlier clinical studies might no longer be applicable to the new Ā»generationsĀ« of upcoming patients. As regards this improved survival, issues of patientās quality of life and possible side-effects of hormonal therapy are also becoming increasingly relevant because hormonal adverse events are time-dependant and tend to increase in severity with prolongation of hormonal manipulation. Therefore, this paper aims to give an overview of the more recent findings, indications and observations regarding hormonal therapy
Lokalno lijeÄenje moždanih metastaza raka dojke
Breast cancer, along with lung cancer and melanoma, is one of the most common origins of central nervous system metastases. Due to improvement of systemic therapy options for primary disease and consequential prolonged survival, treatment of brain metastasis (BM) is presenting an evolving challenge. While new systemic therapy approaches for breast cancer brain metastasis are focusing on overcoming the blood brain and blood tumor barrier, as well as targeted therapies, local therapy remains the primary line of treatment. The decision of which local therapies to use, depends upon the number and volume of BM, their localization, patientās clinical status, previously used treatments, status of extracranial disease and patientās prognosis. In cases when an active approach, including surgery and/or radiotherapy, does not bring benefit to the patientās quality of life or overall survival, best supportive care is recommended.Rak dojke, uz tumore pluÄa te melanom, najÄeÅ”Äi je tumor koji metastazira u srediÅ”nji živÄani sustav. Uslijed razvitka sistemske terapije primarne bolesti, i posljediÄnog produljenog preživljenja bolesnika, lijeÄenje moždanih metastaza predstavlja sve veÄi izazov. Dok se novi pristupi sistemskoj terapiji moždanih presadnica tumora dojke fokusiraju na savladavanje prepreke krvno-moždane i krvno-tumorske barijere te na ciljanu terapiju, lokalna terapija ostaje primarna linija lijeÄenja. Odluka o izboru metode lijeÄenja ovisi o broju i volumenu moždanih presadnica, njihovoj lokalizaciji, kliniÄkom statusu bolesnika, prethodno koriÅ”tenim metodama lijeÄenja, stadiju uznapredovalosti osnovne bolesti te prognozi bolesnika. U sluÄajevima kada aktivni pristup lijeÄenju, koji ukljuÄuje operaciju i/ili radioterapiju, ne pridonosi kvaliteti života ili ukupnom preživljenju bolesnika, preporuÄa se najbolja potporna njega
MULTIPLE PRIMARY MALIGNANCIES
Multipli primarni tumori koji se javljaju kod istog bolesnika, metakrono ili sinkrono, relativno su rijedak dogaÄaj s porastom uÄestalosti posljednjih desetljeÄa. Cilj je ovog istraživanja utvrditi njihovu uÄestalost kod bolesnika lijeÄenih hospitalno u Zavodu za radioterapijsku onkologiju Klinike za onkologiju Medicinskog fakulteta SveuÄiliÅ”ta u Zagrebu, KBC Zagreb u periodu od 2003. do 2009. godine. UÄestalost je multiplih malignih tumora u navedenom periodu bila 2,4%. Od ukupno 103 bolesnika 97 je imalo dva, a 6 tri primarna tumora. Metakronih je tumora bilo 88, a sinkronih 20. UÄestalost im je bila veÄa kod žena nego kod muÅ”karaca, a i pojavljivali su se ranije kod žena nego kod muÅ”karaca. NajÄeÅ”Äe su kombinacije prvog i drugoga metakronog tumora kod muÅ”karaca bile: rak prostate-maligni tumor probavnog sustava (osobito rak rektuma i debelog crijeva) i obrnutim redoslijedom te hematoloÅ”ke zloÄudne bolesti-maligni tumor probavnog sustava; a kod žena: rak dojke-rak kontralateralne dojke i hematoloÅ”ke zloÄudne bolesti (osobito ne-Hodgkinov limfom)-rak dojke. Valja oÄekivati da Äe uÄestalost bolesnika s viÅ”estrukim primarnim tumorima rasti, i zbog programa ranog otkrivanja tumora i zbog uspjeÅ”nijeg lijeÄenja i dužeg oÄekivanog trajanja života.Multiple primary malignancies, metachronous or synchronous, in a single patient are relatively rare event with the increase of incidence in recent decades. The aim of this research is to study their incidence in patients hospitalized at the Division of Radiotherapy, Department of Oncology, University of Zagreb, School of medicine, University Hospital Centre Zagreb from 2003 to 2009. The incidence of multiple primary malignancies was 2.4%. Among 103 patients, 97 had two, and 6 three primary tumors. Eighty-three cases were metachronous, while 20 cases were synchronous malignancies. The frequency was higher in females than males and their age at diagnosis of tumors was younger than in males. The most common tumor combinations in males were: prostate cancer-digestive system malignancy (especially colorectal cancer) and viceversa, and hematological malignant tumors-digestive system malignancy; while in women there were: breast cancer-cancer of contralateral breast and hematological malignant tumors (especially lymphoma non Hodgkin)-breast cancer. The incidence of multiple primary malignancies is expected to increase due to the better screening programs for early detection of malignancies as well as considerable improvement in their treatment and longer life expectancy
Immunotherapy of kidney cancer
Rak je bubrega neoplazma koja je razmjerno otporna na postojeÄu kemoterapiju, hormonsko i iradijacijsko lijeÄenje, stoga se u lijeÄenju bolesnika s rakom bubrega primjenjuju i testiraju lijekovi ili terapije s imunomodulatornim djelovanjem. U kliniÄkoj praksi, a sa svrhom imunoterapije, najÄeÅ”Äe se primjenjuju rekombinantni citokini interferon-alfa (INF-a) i interleukin-2 (IL-2). Ta dva citokina mogu izazvati terapijski odgovor u 10% do 30% bolesnika s metastatskim rakom bubrega. DugoroÄno preživljenje ipak je rijetko, neÅ”to ÄeÅ”Äe u bolesnika koji su primali visokodozni IL-2. Kako lijeÄenje raka bubrega usprkos brojnim studijama s razliÄitim terapijama nije zadovoljavajuÄe, u tijeku su i kliniÄke studije s drugim imunoterapijskim postupcima.Renal cell carcinoma (RCC) is generally resistant to standard chemotherapy, hormonal or irradiation treatments. Therefore, various drugs or therapies with immunomodulatory action were or are tested in kidney cancer patients. In clinical praxis many approaches have been investigated of which interferon-alpha (INF-") and interleukin-2 (IL-2) are the most extensively studied ones. These two cytokines can achieve response rates in 10% to 30% of patients with metastatic RCC. Long-term survival, however, is achieved only in few patients. More frequently in the ones who have been receiving high-dose IL-2. Consequently, the treatment of RCC is far from being optimal. Therefore, other and novel immunotherapeutic strategies are ongoing or planned to be tested in clinical trials